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Abstract
Objectives—There are very few data from men on the risk of HIV acquisition associated with
penile human papillomavirus (HPV) infection and no data on the potential modifying effect of
male circumcision. Therefore, this study evaluated whether HPV is independently associated with
risk of HIV.
Design—A cohort study of HPV natural history nested within a randomized control trial of male
circumcision to reduce HIV incidence in Kisumu, Kenya.
Methods—Prospective data from 2519 men were analyzed using 6-month discrete-time Cox
models to determine if HIV acquisition was higher among circumcised or uncircumcised men with
HPV compared to HPV-uninfected men.
Results—Risk of HIV acquisition was nonsignificantly increased among men with any HPV
[adjusted hazard ratio (aHR) 1.72; 95% confidence interval (CI) 0.94–3.15] and high-risk HPV
(aHR 1.92; 95% CI 0.96–3.87) compared to HPV-uninfected men, and estimates did not differ by
circumcision status. Risk of HIV increased 27% with each additional HPV genotype infection
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(aHR 1.27; 95% CI 1.09–1.48). Men with persistent (aHR 3.27; 95% CI 1.59–6.72) or recently
cleared (aHR 3.05; 95% CI 1.34–6.97) HPV had a higher risk of HIV acquisition than HPV-
uninfected men.
Conclusions—Consistent with the findings in women, HPV infection, clearance, and
persistence were associated with an increased risk of HIV acquisition in men. Given the high
prevalence of HPV in populations at risk of HIV, consideration of HPV in future HIV-prevention
studies and investigation into mechanisms through which HPV might facilitate HIV acquisition
are needed.
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Introduction
Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections
(STIs) worldwide, and the cause of anogenital cancers and warts in both men and women
[1,2]. Recent data among HIV-negative women have shown that cervical HPV infection
increases the risk of HIV acquisition [3–6]. In fact, prospective studies have shown that
women who recently cleared an HPV infection had the highest risk of HIV acquisition
compared to those with no HPV or noncleared HPV infections [3,6,7].
In a previous analysis, limited to examination of only prevalent HPV at study baseline in
uncircumcised men, we found HPV was associated with an increased risk of HIV infection
over the course of 2 years [8], consistent with the findings from a very limited number of
longitudinal studies in men [7,9]. However, given the known impact of male circumcision
on acquisition and clearance of HPVand rate of HIV [10,11], it is important to examine the
risk of HIV acquisition associated with recent penile HPV infection and clearance in both
circumcised and uncircumcised men. Thus, here we build on our previous findings from the
randomized control trial (RCT) of male circumcision in Kisumu, Kenya, to determine if
young men with current, persistent, or recently cleared HPV infections are at a higher risk
for HIV acquisition as compared to men without HPV infection, and to examine the
potential modifying effect of circumcision.
Methods
Study population and design
From 2002 to 2007, an RCT was conducted in Kisumu, Kenya, to determine the
effectiveness of circumcision in reducing the incidence of HIV infection [10]. A cohort
study of the natural history of HPV infections in men was nested within this RCT [12,13].
Briefly, eligible men were 18–24 years old, uncircumcised, HIV-seronegative, sexually
active, and had no current genitourinary symptoms. Of the 2784 men who participated in the
RCT, 2533 consented to and were enrolled in the nested HPV study, of which 2519 had
HPV DNA and HIV serology results at least once during the study period and were included
in the present analysis (1254 immediate circumcision and 1265 delayed circumcision).
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Study visits were conducted at baseline and every 6 months for 24 months for HPV DNA
and for 30 months for HIV serology. At each visit, trained male interviewers administered a
standardized questionnaire on socio-demographic characteristics and sexual behavior. A
physician or clinical officer conducted a physical exam during which a swab (if
symptomatic) or urine sample was collected for PCR detection of Chlamydia trachomatis
and Neisseria gonorrhea (Roche Diagnostics, Alameda, California, USA). Blood was
collected for herpes simplex virus type 2 [HSV-2; ELISA (Kalon Biological Ltd, Aldershot,
UK)] and HIV serology. For HPV DNA detection, penile exfoliated cells were collected
using prewetted Dacron swabs from two separate anatomical sites: glans, coronal sulcus,
and inner foreskin; and shaft and external foreskin [13]. All participants provided informed
consent and all study protocols were approved by Institutional Review Boards at each
collaborating institution.
Determination of HIV and human papillomavirus infection
HIV serostatus at baseline through 30 months of follow-up was determined by on-site rapid
HIV testing [Determine HIV 1/2 (Abbott Diagnostics, Abbott Diagnostic Division,
Hoofddorp, The Netherlands) and Unigold Recombigen HIV (Trinity Biotech, Wicklow,
Ireland)], and confirmed with double ELISA [Detect HIV 1/2 (Aldatis, Rome, Italy) and
Recombigen HIV 1/2 (Trinity Biotech)]. Blood specimens from all participants who tested
positive by at least one rapid test and one ELISA were sent to the Health Canada National
HIV Reference Laboratory (Ottawa, Canada) for confirmatory testing by line immunoassay
[Inno-Lia HIV 1/2 (Immunogenetics NV, Ghent, Belgium)], as previously described [10].
The HIV seroconversion visit (defined as ‘t’) was the first visit at which the participant was
confirmed to be HIV-positive.
Human papillomavirus detection was performed on the shaft and glans samples separately,
and results were pooled from both anatomical sites for statistical analyses. DNA was
isolated from penile cell samples and the presence of human DNA was evaluated by beta-
globin-specific PCR. HPV DNA was assessed by GP5+/6+ PCR followed by reverse line
blot hybridization to detect 44 HPV types, as described previously [14,15]. Any-HPV refers
to infection with any of the 44 genotypes or untyped infections. High-risk HPV (HR-HPV)
refers to HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68, regardless of co-
infection with low-risk or untyped HPV.
Statistical analyses
Crude HIV incidence rates were estimated by the number of seroconversions divided by
person-months of follow-up. An extended Kaplan–Meier method that accommodates time-
varying covariates was employed to nonparametrically estimate and graphically display
cumulative risk of HIV seroconversion by HPV infection status at t – 1 (the visit
immediately preceding the HIV seroconversion visit) [16]. Discrete time Cox models were
used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of the
associations between HPV infection at t – 1 and risk of subsequent HIV acquisition [17].
Any-HPV, HR-HPV, or low-risk HPV (LR-HPV) infection status at the t – 1 visit were
included in the Cox models as time-varying exposures, with time discretized into 6-month
intervals [18,19]. If one HPV result was missing, the previous visit result was carried
Rositch et al. Page 3






















forward, but if more than one HPV result was missing, they remained missing. Because HIV
seroconversion was an uncommon event, estimated coefficients from the fitted Cox models
were interpreted as estimating log risk ratios.
To examine the association between HPV natural history and HIV acquisition, Cox models
were fit using the following four-level covariate: HPV negative at t – 2 and t – 1 (two visits
before the HIV seroconversion visit); HPV persistence only, defined as type-specific HPV
positivity at both t – 2 and t – 1 specific ; HPV clearance only, defined as type-HPV
positivity att – 2 followed by loss of detection of that type at t – 1; and both HPV persistence
and clearance, defined as concurrent cleared and persistent infections since men can have
more than one genotype infection. Because definitions vary in the literature, alternate
comparisons for clearance and persistence were also analyzed:men with cleared infections at
t – 1 regardless of persistence or acquisition of other HPV infections compared to HPV-
negative and men with persistent infections at t – 2 regardless of clearance or acquisition of
other HPV infections compared to HPV-negative.
To assess whether circumcision modified associations between HPV infection and HIV
acquisition, an interaction term was added to the Cox models and statistical tests of
homogeneity (a priori alpha = 0.10) were conducted. Cox models were also run separately
for circumcised and uncircumcised men to examine whether point estimates differed
qualitatively (Online Supplement Table 1, http://links.lww.com/QAD/A424). Variables
associated with both HPV infection and HIV serocon-version in previous analyses
[8,10,12,20] were included as potential confounders in the final multivariate model,
including time-varying HSV-2 serostatus and recent sexual behavior (sex in the past 6
months, but not always with a condom vs. no sex or sex, but always with a condom in the
past 6 months), and baseline age, education, and employment status. It was decided a priori
that time-varying circumcision status should be included in the multivariate model if it was
determined not to be an effect measure modifier.
Results
Population characteristics and risk of HIV acquisition
Of the 2519 men included in this analysis, 61 acquired HIV by 30 months of follow-up
(2.4%). The median time between visits was 6 months [interquartile range (IQR) 6–8] and
median length of follow-up was 30 months (IQR 30–30). Median age at enrollment was 20
years (IQR 19–22) and age was not associated with the risk of HIV acquisition (Table 1).
Men randomized to the immediate circumcision arm were less likely to acquire HIV than
those who remained uncircumcised until the end of the follow-up period (aHR 0.31; 95% CI
0.16–0.62). Men who reported not always using condoms in the past 6 months (aHR 2.03;
95% CI 1.03–3.99) and those who were HSV-2-seropositive (aHR 1.98; 95% CI 1.04–3.76)
were more likely to seroconvert than those who always used condoms or who were HSV-2-
seronegative.
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Human papillomavirus and subsequent risk of HIV acquisition
Of the 61 men who seroconverted over follow-up, 36 were HPV-infected (61%) and 27 were
HR-HPV-infected (46%) (Table 2). The risk of HIV acquisition was over twice as high
among men with any-HPV [unadjusted HR (uHR) 2.55; 95% CI 1.51–4.32] and HR-HPV
(uHR 2.74; 95% CI 1.66–4.79) at the previous visit compared to men who were HPV-
negative. The highest risk of HIV acquisition was among men with HR-HPV, then LR-HPV,
and lowest among uninfected men (P = 0.0003 test for trend). This pattern was consistent
among both circumcised and uncircumcised men (Fig. 1), and there was little evidence of
effect measure modification by circumcision status (Online Supplement Table 1, http://
links.lww.com/QAD/A424; uHR 1.99; 95% CI 1.06–3.77 among uncircumcised and uHR
2.68; 95% CI 1.03–7.01 among circumcised men). After adjusting for circumcision and
other potential confounding variables, the risk of HIV associated with any-HPV (aHR 1.72;
95% CI 0.94–3.15) and HR-HPV infection (aHR 1.92; 95% CI 0.96–3.87) was attenuated
slightly. However, the risk of HIV acquisition increased significantly with each additional
HPV genotype infection (aHR 1.27; 95% CI 1.09–1.48). Men with three or more HPV
infections had over three times the risk of HIV acquisition compared to men who were
HPV-uninfected at the t – 1 visit (aHR 3.45; 95% CI 1.49–7.96).
Type-specific analyses focused on infection with vaccine-preventable HPV types 16 and 18
demonstrated that among the 36 HPV-infected men who HIV-seroconverted, only three
were infected with both HPV-16 and 18, or either of them, alone at t – 1 (Table 3). In
contrast, most HIV seroconverters had both HPV-16 and 18, or either of them, concurrently
with other HPV genotypes (33%), or had only non-16/18 HPV genotypes (58%). Compared
to HPV-uninfected men, the relative risk of HIV acquisition increased in a stepwise fashion
among men HPV-positive for only non-16/18 types, positive for only HPV-16, 18, or both,
and positive for 16/18 with other HPV genotypes.
Human papillomavirus natural history and risk of HIV acquisition
An increased risk of HIV acquisition was observed among men who had recently cleared all
HPV infections (aHR 2.94; 95% CI 1.13–7.57), had only persistent HPV infections (aHR
7.45; 95% CI 2.20–25.37), or who had both cleared and persistent infections (aHR 3.72;
95% CI 1.30–10.57), as compared to men who were HPV-uninfected at t – 1 and t – 2
(Table 4). Alternate natural history definitions (e.g. men with cleared infections regardless
of HPV persistence or acquisition, and men with persistent infections regardless of HPV
clearance or acquisition) resulted in a similar three times increased risk of HIV acquisition
for both HPV clearance and persistence compared to HPV-uninfected men (Table 4; Online
Supplement Fig. 1, http://links.lww.com/QAD/A424).
Discussion
Because recent evidence in women has emerged to suggest that specifically cleared HPV
infections are strongly associated with risk of HIV acquisition and because data in men are
extremely limited, we have now analyzed HPV data collected at 6-month intervals for 2
years in the Kisumu male circumcision trial to determine if HPV infection and natural
history are independently associated with risk of HIV. Incidence of HIV was highest among
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men with persistent and/or recently cleared HPV infections; these men had at least three
times the risk of HIV compared to HPV-uninfected men, independent of HSV-2 and other
potential confounding factors. We found no clear evidence that circumcision modifies the
association between penile HPV infection and risk of HIV acquisition, although
circumcision was strongly associated with acquisition of HIV. Each increase in the number
of concurrent HPV infections was associated with a 27% increased risk of HIV acquisition.
Our results indicate that HPV infection is an important risk factor for HIV acquisition in
men that needs to be explored further and accounted for in HIV-prevention studies.
Our analysis of longitudinal data from an RCT is consistent with previous studies in men
and women showing an increased risk of HIV infection among those with anogenital HPV
infection [3–7,9]. In the few studies that have examined the natural history of HPV
infection, the highest HIV risk was observed among individuals with loss of HPV detection
(i.e. clearance) compared to those with no HPV or persistent HPV infections [3,6,7]. Our
estimate for risk of HIV associated with penile HPV clearance falls within the range of
published relative risk estimates [1.67 (1.03–2.70) to 5.4 (2.9–9.9)] [3,6,7]. Unlike previous
studies, however, we also found a similarly high risk of HIV among men with persistent
HPV infections. A recent case-control analysis of penile HPV infection in predominantly
married men from Rakai, Uganda, found that the relative risk of HIV associated with any-
type persistent HPV was similar to the relative risk of HIV associated with HPV clearance,
although both estimates were nonsignificant [7]. Similar to the present study, slightly
different categorizations of HPV natural history resulted in somewhat different effect
estimates.
Despite differences across studies, the consistently observed association of an increased risk
of HIV acquisition with HPV clearance indicates that the immune-regulatory mechanism
associated with the clearance of HPV may also facilitate HIV acquisition. In a study of
foreskin samples, men who cleared HPV had significantly higher density of dendritic cells,
which deliver HIV virions to CD4+ T cells, a potential explanation for how HPV clearance
might increase susceptibility to HIV seroconversion [7]. However, other plausible
mechanisms have been hypothesized, as reviewed in two recent meta-analyses of risk of
HIV associated with HPV infection [21,22]. Moreover, the risk of HIV acquisition
associated with HPV is unlikely to be fully attributable to confounding by sexual behaviour,
given that effect estimates were similar across strata of recent sexual partners [risk per HPV
infection among men with ≤1 recent partner: aHR 1. 36 (1.15–1.60) vs. + 2 recent partners:
aHR 1. 25 (0.91–1.73)].
It is important to note limitations of our study and ways in which it differs from previous
publications. First, use of GP5+/6+ PCR primers for HPV detection in our study could result
in misclassification of HPV clearance or persistence because they may detect fewer multiple
infections than other L1 primers [23,24]. Second, use of a 6-month interval could potentially
underestimate the true risk of HIV if the association with HPV infection or clearance events
is time-dependent and our measurement was outside the most biologically relevant window.
However, given the 3-month period of uncertainty between the true date of HIV acquisition
and serology-based detection, our use of 6-month time-lagged models ensures that HPV
exposure occurred before HIV acquisition. In addition, our results are similar to our baseline
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HPV analysis and to a previous study using up to 1-year testing intervals [7,8]. Finally, we
defined HPV natural history based on the two time-points prior to HIV seroconversion,
potentially missing earlier clearance or persistence events and not distinguishing between
short and long-term HPV persistence. However, we chose to model HPV events that were
closest in time to HIV acquisition and use time-varying adjustment to account for HPV
status at earlier study visits.
Uncircumcised men tend to have more STI co-infections, higher numbers of HIV target
cells, and a different penile immune environment as compared to circumcised men [25–27].
Therefore, we examined whether the risk of HIV associated with HPV infection could differ
by circumcision status. Our HIV risk estimates associated with HPV differed only slightly
and the P-values for interaction terms (any-HPV* cir-circumcision P = 0.92, and HR-HPV
circumcision P = 0.18) were nonsignificant. Despite the possibility of limited power to
reliably detect effect measure modification due to the modest number of HIV cases, we
conclude that estimates of HIV risk were not qualitatively or quantitatively different
between circumcised and uncircumcised men.
There are currently two vaccines that provide near 100% protection against persistent
infection with HPV-16 and 18, two highly prevalent genotypes that are responsible for 70%
of invasive cervical cancer cases and a relatively smaller fraction of other HPV-associated
cancers. This raises the question as to whether individuals who receive HPV vaccination
will have the added benefit of lowering risk of HIV infection [5,21]. Since there are
currently no data to directly estimate this, we used our observational data to examine risk of
HIV acquisition among men infected with vaccine-preventable types 16/18, taking into
account other concurrent HPV infections. Men with only HPV-16/18 were twice as likely to
acquire HIV infection compared to men who were HPV-negative, but these men represent a
minority of our population. Most HIV seroconverters had only non-16/18 genotype
infections or had HPV-16/18 in addition to other HPV types, and thus would still have HPV
even if vaccinated against HPV-16/18. However, we did find that HIV acquisition was twice
as high among men with HPV-16/18 in addition to other HPV types as compared to men
with only non-16 and 18 infections. The effect of cross-protection against other HR-HPV
types in existing vaccines or a future nonavalent vaccine was not investigated here. In
addition, further research is needed to understand the influence of HPV genotype
independent of number of HPV infections.
Our findings that recently cleared and persistent HPV infections are associated with a
modest increased risk of HIV acquisition, regardless of circumcision status, HSV-2
infection, and other potential confounding factors, are generalizable to other populations of
young, predominately nonmarried, sexually active men from sub-Saharan Africa. In
populations that are at high risk for HIV infection, HPV infection is common, with
prevalence estimates over 50% [12]. Taken together, these findings highlight the need for
further research on potential immunological or behavioral mechanisms underlying these
observational findings. Furthermore, although our data and others may suggest a potential
reduction in HIV risk with a decrease in HPV infection via prophylactic HPV vaccination,
we must be cautious in interpreting these findings in a population with a high prevalence of
known HIV risk factors that would not be affected by HPV vaccination, such as HSV-2
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seropositivity, multiple genital infections, and other sexual risk behaviors such as condom
use [28,29].
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Kaplan–Meier curves displaying the cumulative risk of HIV seroconversion among men
with no HPV infection, LR-HPV types only, and HR-HPV infection at t – 1 among (a) total
population; (b) circumcised men; and (c) uncircumcised men
HPV, human papillomavirus; HR-HPV, high-risk human papillomavirus; LR-HPV, low-risk
human papillomavirus.
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Table 1
Participant characteristics at their first study visit stratified by HIV serostatus at end of study follow-up.
HIV-negative (n = 2458) HIV-seroconverters (n = 61) uHR (95% CI) aHR (95% CI)
N (%) or median (IQR)
Age in years at baseline 20 (19–22) 20 (19–21) 0.98 (0.83–1.15) 0.94 (0.79–1.13)
Randomization group
    Uncircumcised 1218 (50%) 47 (77%) 1 1
    Circumcised 1240 (50%) 14 (23%) 0.35 (0.20–0.61) 0.31 (0.16–0.62)
Employment status
    Unemployed 1580 (64%) 31 (51%) 1 1
    Employed 878 (36%) 30 (49%) 2.05 (1.16–3.61) 1.72 (0.91–3.25)
Education
    Any secondary or above 1610 (66%) 33 (54%) 1 1
    Less than secondary 848 (34%) 28 (46%) 1.97 (1.12–3.48) 1.27 (0.68–2.37)
Sexual behavior, previous 6 months
    No sex or sex always with condoms
a 843 (34%) 14 (23%) 1 1
    Sex not always with condoms 1613 (66%) 47 (77%) 2.55 (1.32–4.92) 2.03 (1.03–3.99)
Any-HPV DNA
    No 1279 (52%) 21 (34%) 1 1
    Yes 1179 (48%) 40 (66%) 2.55 (1.51–4.32) 1.72 (0.94–3.15)
Herpes simplex virus 2
    Seronegative 1547 (74%) 32 (62%) 1 1
    Seropositive 549 (26%) 19 (37%) 2.04 (1.17–3.54) 1.98 (1.04–3.76)
Gonorrhea or Chlamydia
    No 2308 (94%) 57 (93%) 1 1
    Yes 147 (6%) 4 (7%) 0.95 (0.23–3.92) 0.99 (0.24–4.18)
aHR, adjusted hazard ratio; CI, confidence interval; HPV, human papillomavirus; IQR, interquartile range; uHR, unadjusted hazard ratio. Missing
data: employment (n = 0), education (n = 0), recent sexual behavior (n = 2), herpes simplex virus 2 (n = 372), gonorrhea and chlamydia (n = 3).
a
Includes men reporting no sex in previous 6 months (n = 326).
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Table 2
HPV infection status at the visit prior to HIV seroconversion.
No. of HIV seroconverters Incidence rate (95% CI)
a uHR (95% CI) aHR (95% CI)
HPV infection
    No HPV 23 0.54 (0.32–0.76) 1 1
        Any-HPV 36 1.33 (0.90–1.76) 2.55 (1.51–4.32) 1.72 (0.94–3.15)
    No HPV 23 0.54 (0.32–0.76) 1 1
        LR-HPV 9 1.10 (0.34–1.85) 2.04 (0.95–4.40) 1.25 (0.45–3.42)
        HR-HPV 27 1.54 (0.94–2.14) 2.74 (1.66–4.79) 1.92 (0.96–3.87)
Number of HPV infections
    0 types 23 0.54 (0.32–0.76) 1 1
        1–2 types 22 1.01 (0.55–1.48) 1.70 (0.90–3.23) 1.41 (0.64–3.13)
        ≥3 types 14 2.68 (1.38–3.99) 4.92 (2.55–9.47) 3.45 (1.49–7.96)
    Risk per additional genotype 59 1.33 (1.22–1.48) 1.27 (1.09–1.48)
aHR, adjusted hazard ratio; CI, confidence interval; HR-HPV, high-risk human papillomavirus; LR-HPV, low-risk human papillomavirus; uHR,
unadjusted hazard ratio.
a
Incidence rates are expressed as infections per 1000 person-months.
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Table 3
Infection with vaccine and nonvaccine-preventable HPV types and risk of HIV seroconversion.
No. of HIV seroconverters uHR (95% CI) aHR (95% CI)
HPV-negative 23 1 1
HPV-positive with non-16/18 21 2.38 (1.23–4.34) 1.38 (0.69–2.78)
HPV-16 and/or 18 positive only 3 2.07 (0.45–8.87) 2.11 (0.51–9.05)
HPV-16 and/or 18 with other types 12 5.69 (2.74–11.93) 4.28 (1.95–9.33)
aHR, adjusted hazard ratio; CI, confidence interval; HPV, human papillomavirus; uHR, unadjusted hazard ratio.
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Table 4
HPV natural history and subsequent risk of HIV seroconversion.
No. of HIV
seroconverters
Incidence rate per 1000
person-months (95% CI)
uHR (95% CI) aHR (95% CI)
HPV natural history
a
HPV-uninfected 20 0.44 (0.27–0.60) 1 1
    Clearance, only 19 0.85 (0.47–1.23) 2.12 (1.05–4.33) 2.94 (1.13–7.57)
    Persistence, only 4 2.50 (0.07–4.93) 5.17 (1.68–15.84) 7.45 (2.20–25.37)
    Clearance + Persistence 11 2.64 (1.09–4.18) 5.76 (2.57–12.87) 3.72 (1.30–10.57)
Alternate natural history definitions
    HPV-uninfected 20 0.44 (0.27–0.60) 1 1
    Cleared infections 30 1.18 (0.75–1.60) 2.78 (1.43–5.39) 3.05 (1.34–6.97)
    HPV-uninfected 20 0.44 (0.27–0.60) 1 1
    Persistent infections 15 1.92 (1.06–2.77) 4.41 (2.28 –8.47) 3.27 (1.59–6.72)
aHR, adjusted hazard ratio; CI, confidence interval; HPV, human papillomavirus; uHR, unadjusted hazard ratio.
a
Mutually exclusive categories were defined as HPV-negative at t – 2 and t – 1; HPV persistence only, defined as type-specific HPV positivity at
both t – 2 and t – 1; HPV clearance only, defined as type-specific HPV positivity at t – 2 followed by loss of detection of that type at t – 1; and
HPV persistence and clearance, defined as concurrent cleared and persistent infections since men can have more than one type infection with
different natural histories at t – 2 and t – 1.
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